Research programme: neurodegenerative disease therapies - Cambria Pharmaceuticals

Drug Profile

Research programme: neurodegenerative disease therapies - Cambria Pharmaceuticals

Alternative Names: CMB-03350; CMB-44282; CMB-50213; CMB-50381; CMB-53042

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Cambria Biosciences LLC
  • Developer Cambria Pharmaceuticals; Northwestern University
  • Class Small molecules
  • Mechanism of Action Superoxide dismutase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Amyotrophic lateral sclerosis; Cerebral ischaemia
  • Discontinued Brain injuries; Parkinson's disease

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA
  • 16 Jul 2016 No recent reports of development identified for research development in Cerebral-ischaemia in USA
  • 07 Nov 2007 Pharmacodynamics data from an in vitro study in Amyotrophic lateral sclerosis presented at the 37th Annual Meeting of the Society for Neuroscience (SfN-2007)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top